Ursolic acid was shown to halt the progression of chronic multiple sclerosis (MS) and reverse the damage already caused in a mouse model of the disease.
List view / Grid view
Multiple Sclerosis (MS)
Filter the results
Researchers observed that deleting the IRE1-alpha gene caused beta cells to de-differentiate and then re-differentiate in mice, preventing immune system auto-activation.
Research into age-related chronic inflammatory disorders has identified an ‘off switch’ on the NLRP3 inflammasome that could be targeted in new therapies.
Researchers have revealed that inhibiting IL-17 could prevent the effects of autoimmune diseases, including multiple sclerosis.
Research into the structure of the drug-integrin complex has enabled the creation of drugs which inhibit integrin as effectively as currently used compounds, without causing excessive bleeding.
Drug Target Review lists its 10 most popular news stories from 2019, summarising the drug targets that you wanted to read about.
A study has found a new molecular process in mice that causes autoimmune diseases and has opened avenues for developing more effective autoimmune therapies.
In a pre-clinical model of multiple sclerosis, orally treating susceptible mice with a microRNA from the diseased gut has prevented the disease.
A study has discovered that the PKM2 protein plays a role in regulating immune cells and blocking this could be a potential treatment for inflammatory diseases.
Researchers have identified a protein on the surface of cells that cause MS and have used antibodies as an effective treatment for the condition in mice.
A compound that promotes the rebuilding of the protective sheath around nerve cells damaged in multiple sclerosis has been developed.
A research team has developed a method for regenerating old brain stem cells from rat models, which could be used to treat age-related brain diseases.